These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 338644)

  • 21. Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function.
    Bressolle F; Brès J; Mourad G
    Clin Pharmacokinet; 1989 Nov; 17(5):367-73. PubMed ID: 2582694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Iodamide-300 and 380: evaluation of the results of clinical trials in angiography and urography].
    Absava GI; Rabkin IKh; Rozenshtraukh LS; Krivenko EV
    Vestn Rentgenol Radiol; 1986; (1):74-7. PubMed ID: 3518227
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacokinetics of iohexol, a new nonionic radiocontrast agent, in humans.
    Edelson J; Shaw D; Palace G
    J Pharm Sci; 1984 Jul; 73(7):993-5. PubMed ID: 6470969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical experiences with the new contrast medium iodamide 420 (author's transl)].
    Fráter LL; Száva J; Gaál T; Kertész E
    Rontgenblatter; 1978 Jan; 31(1):38-45. PubMed ID: 622530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Total contrast media (iodamide) excretion time in infusion urography].
    Giordano A; Aguzzi F
    Minerva Urol; 1973; 25(4):171-4. PubMed ID: 4771851
    [No Abstract]   [Full Text] [Related]  

  • 26. Cefamandole pharmacokinetics and dosage adjustments in relation to renal function.
    Brogard JM; Kopferschmitt J; Spach MO; Grudet O; Lavillaureix J
    J Clin Pharmacol; 1979 Jul; 19(7):366-77. PubMed ID: 479381
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of enprofylline in patients with impaired renal function after a single intravenous dose.
    Lunell E; Borgå O; Larsson R
    Eur J Clin Pharmacol; 1984; 26(1):87-93. PubMed ID: 6714295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of temocillin (BRL 17421) in subjects with normal and impaired renal function.
    Leroy A; Humbert G; Fillastre JP; Borsa F; Godin M
    J Antimicrob Chemother; 1983 Jul; 12(1):47-58. PubMed ID: 6619046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function.
    Arancibia A; Drouguett MT; Fuentes G; González G; González C; Thambo S; Palombo G
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):447-53. PubMed ID: 7141752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition of the cephalosporin cefepime in normal and renally impaired subjects.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Halstenson CE; Opsahl JA; Pittman KA
    Drug Metab Dispos; 1991; 19(1):68-73. PubMed ID: 1673424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urography in children with renal failure using different contrast media.
    Sarperi M; Tomà P; Rebaudo M; Schroembgens P; Perfumo F; Gusmano R
    Rays; 1985; 10(1):23-30. PubMed ID: 3843631
    [No Abstract]   [Full Text] [Related]  

  • 32. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.
    Sobue S; Tan K; Layton G; Leclerc V; Weil A
    Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of sisomicin in patients with normal and impaired renal function; its efficacy in urinary tract infection.
    Roth S; Naber K; Scheer M; Gruenwaldt G; Lange H
    Eur J Clin Pharmacol; 1976 Sep; 10(5):357-65. PubMed ID: 789084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition of intravenous pirmenol.
    Sanders SW; Nappi JM; Foltz RL; Lutz JR; Anderson JL
    J Clin Pharmacol; 1983; 23(2-3):113-22. PubMed ID: 6853743
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of intravenous amikacin after rapid and slow infusion with special reference to hemodialysis.
    Pechere JC; Dugal R; Pechere MM
    Eur J Drug Metab Pharmacokinet; 1979; 4(1):49-56. PubMed ID: 467467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function.
    Guay DR; Matzke GR; Bockbrader HN; Dancik J
    Clin Pharm; 1983; 2(2):157-62. PubMed ID: 6883944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of tocainide in patients with combined hepatic and renal dysfunction.
    Oltmanns D; Pottage A; Endell W
    Eur J Clin Pharmacol; 1983; 25(6):787-90. PubMed ID: 6420165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiopaque contrast media. XLIII. Physicochemical properties of iodamide, an intravenous uro-angiographic contrast agent.
    Felder E; Pitrè D; Grandi M
    Farmaco Sci; 1977 Oct; 32(10):755-65. PubMed ID: 21810
    [No Abstract]   [Full Text] [Related]  

  • 40. Measurement of N tau-methylhistamine concentrations in urine as a parameter for histamine release by radiographic contrast media.
    Keyzer JJ; Udding H; de Vries K
    Diagn Imaging Clin Med; 1984; 53(2):67-72. PubMed ID: 6200265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.